{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:35:41Z","timestamp":1790768141190,"version":"4.1.0"},"reference-count":102,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The growing elderly population worldwide represents a major challenge for caregivers, healthcare providers, and society. Older patients have a higher prevalence of cardiovascular (CV) disease, high rates of CV risk factors, and multiple age-related comorbidities. Although prevention and management strategies have been shown to be effective in older people, they continue to be under-used, and under-studied. In addition to hard endpoints, frailty, cognitive impairments, and patients\u2019 re-assessment of important outcomes (e.g. quality of life vs. longevity) are important aspects for older patients and emphasize the need to include a substantial proportion of older patients in CV clinical trials. To complement the often skewed age distribution in clinical trials, greater emphasis should be placed on real-world studies to assess longer-term outcomes, especially safety and quality of life outcomes. In the complex environment of the older patient, a multidisciplinary care team approach with the involvement of the individual patient in the decision-making process can help optimize prevention and management strategies. This article aims to demonstrate the growing burden of ageing in real life and illustrates the need to continue primary prevention to address CV risk factors. It summarizes factors to consider when choosing pharmacological and interventional treatments for the elderly and the need to consider quality of life and patient priorities when making decisions.<\/jats:p>","DOI":"10.1093\/eurjpc\/zwac033","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T04:12:59Z","timestamp":1644552779000},"page":"1412-1424","source":"Crossref","is-referenced-by-count":68,"title":["Cardiovascular disease in the elderly: proceedings of the European Society of Cardiology\u2014Cardiovascular Round Table"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0146-9196","authenticated-orcid":false,"given":"Maddalena","family":"Lettino","sequence":"first","affiliation":[{"name":"Cardiovascular Department, San Gerardo Hospital of Monza , Via G. B. Pergolesi, 33, 20900 Monza MB , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7478-1450","authenticated-orcid":false,"given":"Julia","family":"Mascherbauer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Karl Landsteiner University of Health Sciences, University Hospital St. P\u00f6lten , Krems , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1760-1550","authenticated-orcid":false,"given":"Matias","family":"Nordaby","sequence":"additional","affiliation":[{"name":"Heart Failure, Boehringer-Ingelheim , Ingelheim am Rhein , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Ziegler","sequence":"additional","affiliation":[{"name":"Cardiovascular Diseases, Roche Diagnostics , Rotkreuz , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Philippe","family":"Collet","sequence":"additional","affiliation":[{"name":"ACTION Group, www.action-groupe.org, Sorbonne Universit\u00e9, INSERM UMRS1166, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re (AP-HP), Institut de Cardiologie , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevi\u00e8ve","family":"Derumeaux","sequence":"additional","affiliation":[{"name":"Physiology Department, Henri Mondor Hospital (APHP), FHU SENEC , Cr\u00e9teil , France"},{"name":"Mondor Biomedical Research Institute (IMRB), UPEC , Cr\u00e9teil , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan H","family":"Hohnloser","sequence":"additional","affiliation":[{"name":"Department of Electrophysiology, J.W. Goethe University , Frankfurt , Germany"},{"name":"Center of Thrombosis and Hemostasis, University of Mainz , Mainz , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Leclercq","sequence":"additional","affiliation":[{"name":"Department of Cardiology, CHU Rennes and Inserm, LTSI, University of Rennes , Rennes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre E","family":"O'Neill","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Alberta Hospital , Edmonton, Alberta , Canada"},{"name":"Mazankowski Heart Institute , Edmonton, Alberta , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Visseren","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, University Medical Center , Utrecht , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0829-9097","authenticated-orcid":false,"given":"Franz","family":"Weidinger","sequence":"additional","affiliation":[{"name":"2nd Medical Dept. with Cardiology and Intensive Care Medicine, Hospital Rudolfstiftung , Vienna , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Richard-Lordereau","sequence":"additional","affiliation":[{"name":"General Medicine Europe, Amgen Europe , Rotkreutz ZG , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"2022080516195196200_zwac033-B1","author":"Eurostat","year":"2021"},{"key":"2022080516195196200_zwac033-B2","author":"Eurostat"},{"key":"2022080516195196200_zwac033-B3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/jcdd6020019","article-title":"Cardiovascular risks associated with gender and aging","volume":"6","author":"Rodgers","year":"2019","journal-title":"J Cardiovasc Dev Dis"},{"key":"2022080516195196200_zwac033-B4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000494025","article-title":"How to measure population aging? The answer is less than obvious: a review","volume":"65","author":"Skirbekk","year":"2019","journal-title":"Gerontology"},{"key":"2022080516195196200_zwac033-B5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/0958928716676550","article-title":"Measuring active and healthy ageing in Europe","volume":"27","author":"Zaidi","year":"2017","journal-title":"J Eur Social Policy"},{"key":"2022080516195196200_zwac033-B6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4321\/S1886-36552014000400007","article-title":"Defining \u2018elderly\u2019 in clinical practice guidelines for pharmacotherapy","volume":"12","author":"Singh","year":"2014","journal-title":"Pharm Pract (Granada)"},{"key":"2022080516195196200_zwac033-B7","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","author":"Score2-OP Working Group and ESC Cardiovascular Risk Collaboration","year":"2021","journal-title":"Eur Heart J"},{"key":"2022080516195196200_zwac033-B8","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2022080516195196200_zwac033-B9","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/eurheartj\/ehz239","article-title":"Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people","volume":"41","author":"Jaspers","year":"2020","journal-title":"Eur Heart J"},{"key":"2022080516195196200_zwac033-B10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00392-016-1023-8","article-title":"Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients","volume":"106","author":"Stam-Slob","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"2022080516195196200_zwac033-B11","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1177\/2047487315588390","article-title":"Cardiovascular risk estimation in older persons: SCORE O.P","volume":"23","author":"Cooney","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2022080516195196200_zwac033-B12","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1177\/2047487319846715","article-title":"Risk prediction tools in cardiovascular disease prevention: a report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP)","volume":"26","author":"Rossello","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2022080516195196200_zwac033-B13","doi-asserted-by":"crossref","first-page":"e016115","DOI":"10.1161\/JAHA.120.016115","article-title":"Challenges and opportunities for the prevention and treatment of cardiovascular disease among young adults: Report from a National Heart, Lung, and Blood Institute Working Group","volume":"9","author":"Gooding","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2022080516195196200_zwac033-B14","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"2022080516195196200_zwac033-B15","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.jacc.2019.03.467","article-title":"Deprescribing in older adults with cardiovascular disease","volume":"73","author":"Krishnaswami","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022080516195196200_zwac033-B16","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1016\/j.jacc.2019.04.020","article-title":"Cognitive decline before and after incident coronary heart disease: opportunity to intervene cognitive function trajectories","volume":"73","author":"Rovio","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022080516195196200_zwac033-B17","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1177\/2047487316632364","article-title":"High-sensitivity cardiac troponin T is associated with cognitive decline in older adults at high cardiovascular risk","volume":"23","author":"Wijsman","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2022080516195196200_zwac033-B18","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/j.jacc.2019.04.019","article-title":"Cognitive decline before and after incident coronary events","volume":"73","author":"Xie","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022080516195196200_zwac033-B19","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"2022080516195196200_zwac033-B20","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)","volume":"265","author":"SHEP Cooperative Research Group","year":"1991","journal-title":"JAMA"},{"key":"2022080516195196200_zwac033-B21","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","article-title":"Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension","volume":"350","author":"Staessen","year":"1997","journal-title":"Lancet"},{"key":"2022080516195196200_zwac033-B22","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"key":"2022080516195196200_zwac033-B23","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Sprint Research Group","year":"2015","journal-title":"N EnglJ Med"},{"key":"2022080516195196200_zwac033-B24","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1161\/CIRCULATIONAHA.116.025322","article-title":"Potential deaths averted and serious adverse events incurred from adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) intensive blood pressure regimen in the United States: projections from NHANES (National Health and Nutrition Examination Survey)","volume":"135","author":"Bress","year":"2017","journal-title":"Circulation"},{"key":"2022080516195196200_zwac033-B25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12916-015-0328-1","article-title":"No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over","volume":"13","author":"Warwick","year":"2015","journal-title":"BMC Med"},{"key":"2022080516195196200_zwac033-B26","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1001\/jama.2016.7050","article-title":"Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged &gt;\/=75 years: a randomized clinical trial","volume":"315","author":"Williamson","year":"2016","journal-title":"JAMA"},{"key":"2022080516195196200_zwac033-B27","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1161\/CIRCRESAHA.118.313236","article-title":"Hypertension management in older and frail older patients","volume":"124","author":"Benetos","year":"2019","journal-title":"Circ Res"},{"key":"2022080516195196200_zwac033-B28","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2022080516195196200_zwac033-B29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","author":"Cholesterol Treatment Trialists","year":"2019","journal-title":"Lancet"},{"key":"2022080516195196200_zwac033-B30","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jacc.2013.07.069","article-title":"Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis","volume":"62","author":"Savarese","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022080516195196200_zwac033-B31","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"2022080516195196200_zwac033-B32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamainternmed.2020.6084","article-title":"Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: a meta-analysis","volume":"181","author":"Yourman","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2022080516195196200_zwac033-B33","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40266-013-0095-7","article-title":"Rationalizing prescribing for older patients with multimorbidity: considering time to benefit","volume":"30","author":"Holmes","year":"2013","journal-title":"Drugs Aging"},{"key":"2022080516195196200_zwac033-B34","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022080516195196200_zwac033-B35","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/ageing\/afz096","article-title":"Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME(R) trial","volume":"48","author":"Monteiro","year":"2019","journal-title":"Age Ageing"},{"key":"2022080516195196200_zwac033-B36","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/dc19-1476","article-title":"Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study","volume":"43","author":"Cahn","year":"2020","journal-title":"Diabetes Care"},{"key":"2022080516195196200_zwac033-B37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-019-0871-8","article-title":"Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial","volume":"18","author":"Leiter","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2022080516195196200_zwac033-B38","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1210\/clinem\/dgab065","article-title":"Efficacy and safety of dulaglutide in older patients: a post hoc analysis of the REWIND trial","volume":"106","author":"Riddle","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2022080516195196200_zwac033-B39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.7326\/M18-1569","article-title":"Effect of liraglutide on cardiovascular outcomes in elderly patients: a post hoc analysis of a randomized controlled trial","volume":"170","author":"Gilbert","year":"2019","journal-title":"Ann Intern Med"},{"key":"2022080516195196200_zwac033-B40","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"2022080516195196200_zwac033-B41","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"2022080516195196200_zwac033-B42","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"ASCEND Study","year":"2018","journal-title":"N EnglJ Med"},{"key":"2022080516195196200_zwac033-B43","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"2022080516195196200_zwac033-B44","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"Effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"key":"2022080516195196200_zwac033-B45","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults","volume":"67","author":"By the American Geriatrics Society Beers Criteria Update Expert Panel","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"2022080516195196200_zwac033-B46","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cjca.2020.02.086","article-title":"Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children","volume":"36","author":"Rabi","year":"2020","journal-title":"Can J Cardiol"},{"key":"2022080516195196200_zwac033-B47","doi-asserted-by":"crossref","first-page":"h1551","DOI":"10.1136\/bmj.h1551","article-title":"Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium","volume":"350","author":"Mons","year":"2015","journal-title":"BMJ"},{"key":"2022080516195196200_zwac033-B48","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.114.001885","article-title":"Risk of heart failure and death after prolonged smoking cessation: role of amount and duration of prior smoking","volume":"8","author":"Ahmed","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2022080516195196200_zwac033-B49","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet","volume":"368","author":"Estruch","year":"2013","journal-title":"N Engl J Med"},{"key":"2022080516195196200_zwac033-B50","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/bmj.38415.644155.8F","article-title":"Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study","volume":"330","author":"Trichopoulou","year":"2005","journal-title":"BMJ"},{"key":"2022080516195196200_zwac033-B51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/01.CIR.100.1.9","article-title":"Effects of walking on coronary heart disease in elderly men: the Honolulu Heart Program","volume":"100","author":"Hakim","year":"1999","journal-title":"Circulation"},{"key":"2022080516195196200_zwac033-B52","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1001\/archinte.158.14.1499","article-title":"Physical activity and 10-year mortality from cardiovascular diseases and all causes: the Zutphen Elderly Study","volume":"158","author":"Bijnen","year":"1998","journal-title":"Arch Intern Med"},{"key":"2022080516195196200_zwac033-B53","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijge.2013.03.001","article-title":"Physical activity and risk of cardiovascular disease among older adults","volume":"7","author":"Cheng","year":"2013","journal-title":"Int J Gerontology"},{"key":"2022080516195196200_zwac033-B54","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamainternmed.2015.0289","article-title":"Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial","volume":"175","author":"Kutner","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2022080516195196200_zwac033-B55","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jamda.2018.10.026","article-title":"Health outcomes of deprescribing interventions among older residents in nursing homes: a systematic review and meta-analysis","volume":"20","author":"Kua","year":"2019","journal-title":"J Am Med Dir Assoc"},{"key":"2022080516195196200_zwac033-B56","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12877-021-02208-8","article-title":"A systematic review of the evidence for deprescribing interventions among older people living with frailty","volume":"21","author":"Ibrahim","year":"2021","journal-title":"BMC Geriatr"},{"key":"2022080516195196200_zwac033-B57","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12944-020-01277-9","article-title":"Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study","volume":"19","author":"Rosada","year":"2020","journal-title":"Lipids Health Dis"},{"key":"2022080516195196200_zwac033-B58","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","article-title":"Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials","volume":"396","author":"Gencer","year":"2020","journal-title":"Lancet"},{"key":"2022080516195196200_zwac033-B59","author":"A Clinical Trial of Statin Therapy for Reducing Events in the Elderly (STAREE)","year":"2021"},{"key":"2022080516195196200_zwac033-B60","author":"Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults (PREVENTABLE)","year":"2021"},{"key":"2022080516195196200_zwac033-B61","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000501745","article-title":"Aging is a powerful risk factor for type 2 diabetes mellitus independent of body mass index","volume":"66","author":"Fazeli","year":"2020","journal-title":"Gerontology"},{"key":"2022080516195196200_zwac033-B62","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2019.03.501","article-title":"Aspirin for primary prevention of cardiovascular events","volume":"73","author":"Abdelaziz","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022080516195196200_zwac033-B63","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jnci\/djaa115","article-title":"The ASPREE trial: An unanticipated stimulus for greater precision in prevention?","volume":"113","author":"Hawk","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2022080516195196200_zwac033-B64","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4140\/TCP.n.2019.580","article-title":"Aspirin use for primary prevention of cardiovascular disease in older patients: a review of clinical guidelines and updated evidence","volume":"34","author":"Lewis","year":"2019","journal-title":"Sr Care Pharm"},{"key":"2022080516195196200_zwac033-B65","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1161\/CIRCULATIONAHA.104.521708","article-title":"Role of smoking in global and regional cardiovascular mortality","volume":"112","author":"Ezzati","year":"2005","journal-title":"Circulation"},{"key":"2022080516195196200_zwac033-B66","first-page":"CD011114","article-title":"Vitamin C supplementation for the primary prevention of cardiovascular disease","volume":"3","author":"Al-Khudairy","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2022080516195196200_zwac033-B67","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jamacardio.2019.1870","article-title":"Vitamin D supplementation and cardiovascular disease risks in more than 83000 individuals in 21 randomized clinical trials: a meta-analysis","volume":"4","author":"Barbarawi","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2022080516195196200_zwac033-B68","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1001\/jama.2008.600","article-title":"Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial","volume":"300","author":"Sesso","year":"2008","journal-title":"JAMA"},{"key":"2022080516195196200_zwac033-B69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1809944","article-title":"Vitamin D supplements and prevention of cancer and cardiovascular disease","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"key":"2022080516195196200_zwac033-B70","first-page":"CD003177","article-title":"Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease","volume":"3","author":"Abdelhamid","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2022080516195196200_zwac033-B71","doi-asserted-by":"crossref","first-page":"100997","DOI":"10.1016\/j.eclinm.2021.100997","article-title":"Effect of omega-3 fatty acids on cardiovascular outcomes: a systematic review and meta-analysis","volume":"38","author":"Khan","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2022080516195196200_zwac033-B72","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/eurheartj\/ehz768","article-title":"Changes in exercise frequency and cardiovascular outcomes in older adults","volume":"41","author":"Kim","year":"2020","journal-title":"Eur Heart J"},{"key":"2022080516195196200_zwac033-B73","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/2047487317737628","article-title":"Impact of physical activity on the risk of cardiovascular disease in middle-aged and older adults: EPIC Norfolk prospective population study","volume":"25","author":"Lachman","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"2022080516195196200_zwac033-B74","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2022080516195196200_zwac033-B75","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/archinte.1995.00430050045005","article-title":"Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications","volume":"155","author":"Feinberg","year":"1995","journal-title":"Arch Intern Med"},{"key":"2022080516195196200_zwac033-B76","first-page":"718","article-title":"Efficacy and safety of novel anticoagulants in the elderly","volume":"13","author":"Karamichalakis","year":"2016","journal-title":"J Geriatr Cardiol"},{"key":"2022080516195196200_zwac033-B77","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10557-020-06981-3","article-title":"Anticoagulants for stroke prevention in atrial fibrillation in elderly patients","volume":"34","author":"Schafer","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"2022080516195196200_zwac033-B78","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2022080516195196200_zwac033-B79","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/cce2.55","article-title":"Management of atrial fibrillation and concomitant coronary artery disease","volume":"3","author":"Martin","year":"2017","journal-title":"Cont Cardiol Educ"},{"key":"2022080516195196200_zwac033-B80","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"},{"key":"2022080516195196200_zwac033-B81","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"2022080516195196200_zwac033-B82","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"2022080516195196200_zwac033-B83","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/2047487317707854","article-title":"Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease","volume":"24","author":"Lettino","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"2022080516195196200_zwac033-B84","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2147\/CIA.S252318","article-title":"Percutaneous coronary intervention in elderly patients with coronary chronic total occlusions: Current evidence and future perspectives","volume":"15","author":"Guo","year":"2020","journal-title":"Clin Interv Aging"},{"key":"2022080516195196200_zwac033-B85","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"2022080516195196200_zwac033-B86","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","article-title":"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery","volume":"363","author":"Leon","year":"2010","journal-title":"N Engl J Med"},{"key":"2022080516195196200_zwac033-B87","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ccd.28163","article-title":"Impact of revascularization versus medical therapy alone for chronic total occlusion management in older patients","volume":"94","author":"Flores-Umanzor","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"2022080516195196200_zwac033-B88","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(01)06100-1","article-title":"Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial","volume":"358","author":"Time Investigators","year":"2001","journal-title":"Lancet"},{"key":"2022080516195196200_zwac033-B89","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"2022080516195196200_zwac033-B90","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/S0140-6736(09)60552-3","article-title":"Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials","volume":"373","author":"Hlatky","year":"2009","journal-title":"Lancet"},{"key":"2022080516195196200_zwac033-B91","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/S0140-6736(21)02334-5","article-title":"Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis","volume":"398","author":"Sabatine","year":"2021","journal-title":"Lancet"},{"key":"2022080516195196200_zwac033-B92","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/eurheartj\/ehy532","article-title":"Considerations for the choice between coronary artery bypass grafting and percutaneous coronary intervention as revascularization strategies in major categories of patients with stable multivessel coronary artery disease: an accompanying article of the task force of the 2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Windecker","year":"2019","journal-title":"Eur Heart J"},{"key":"2022080516195196200_zwac033-B93","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2021","journal-title":"Eur Heart J"},{"key":"2022080516195196200_zwac033-B94","article-title":"Aortic Valve ReplAcemenT versus Conservative Treatment in Asymptomatic SeveRe Aortic Stenosis: the AVATAR trial","author":"Banovic","year":"2021","journal-title":"Circulation"},{"key":"2022080516195196200_zwac033-B95","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1093\/eurheartj\/ehz275","article-title":"Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis","volume":"40","author":"Siontis","year":"2019","journal-title":"Eur Heart J"},{"key":"2022080516195196200_zwac033-B96","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"2022080516195196200_zwac033-B97","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jcin.2021.06.020","article-title":"Antithrombotic therapy after transcatheter aortic valve replacement","volume":"14","author":"Capodanno","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2022080516195196200_zwac033-B98","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.jcin.2020.07.044","article-title":"Delirium after TAVR: crosspassing the limit of resilience","volume":"13","author":"van der Wulp","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"2022080516195196200_zwac033-B99","first-page":"326","article-title":"The importance of palliative care in cardiology: differences between countries","volume":"2","author":"Kilic","year":"2020","journal-title":"J Am Coll Cardiol Case Rep"},{"key":"2022080516195196200_zwac033-B100","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N Engl J Med"},{"key":"2022080516195196200_zwac033-B101","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jacc.2017.05.030","article-title":"Palliative care in heart failure: the PAL-HF randomized, controlled clinical trial","volume":"70","author":"Rogers","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022080516195196200_zwac033-B102","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwac033\/42946863\/zwac033.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/29\/10\/1412\/45276691\/zwac033.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/29\/10\/1412\/45276691\/zwac033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T09:14:35Z","timestamp":1700212475000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/29\/10\/1412\/6529006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":102,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,2,15]]},"published-print":{"date-parts":[[2022,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwac033","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,2,15]]}}}